BackgroundStudies evaluating the difference between men and women diagnosed of scleroderma (SSc) are scarce (1-5) because of the shortage of male patients.ObjectivesAssessing the existence of differences in clinical presentation and mortality causes among men and women in a large cohort of Spanish patients diagnosed with SSc.MethodsA registry of patients with SSc has been performed by the Spanish network for systemic sclerosis (RESCLE) since 2008, in which 90 clinical, immunological and capillaroscopic variables were collected prospectively. Data were collected until May 2014 for this study.Results1506 patients (1341 women), were included. Overall ratio female/male was 8/1. By subtypes lcSSc and preSSc were more frequent in females [84 (51%) vs 808 (60%), p0.023; 6 (3.6%) vs100 (7.5%), p0.076, respectively] and dcSSc in males [62 (38%) vs 293 (22%), p<0.001]. Diagnostic delay was longer in women (2.92 yrs vs 1.30yrs, p<0.001) and smoking was more prevalent in men. Myositis, tendon rubs, interstitial lung disease (ILD), cardiac conduction disturbances and renal crisis were more frequent in males, while isolated pulmonary arterial hypertension (PAH) and sicca syndrome in women. Positivity for ANA, ACA and antiRo was more frequent in women and antiScl-70 and antiRNA pol III in men. There were no sex differences in capillaroscopic patterns. In the multivariate study remained significant in the male predominance in smoking (OR 2.33, CI 1.49 to 4.14, p=0.002) and ILD (OR 1.70, CI 1.11 to 2 60, p=0.015) and in women sicca syndrome (OR 3, 1.63 to 5.52) and ANA positivity (OR 2.67, 1.29 to 5.51).Follow-up time (years) since the onset of symptoms was in males 8.69 yrs vs women 11.79, p=0.001. Altogether, 261 patients died (17%). Although there was no difference in the age at death, this was more common in men (31% men vs 15% women), and time from the onset of symptoms to death was longer in women [14.06 yrs (5.95 to 24.29) vs 8.33 (3.87 to 12.66), p<0.001]. Death was related to SSc in 112 (46%) (22 males vs 90 in women, p ns) while 129 (54%) (31 males vs. 103 for females, p ns) were due to other causes. ILD was the most common cause of death in men (27,5%) and PH in women (28,6%). PAH was more frequently a cause of death in women 39 (19,9%) than in men 0 (0,0%), p<0,001. The cumulative survival at 20 years from onset was 90.9% in women versus 76.3% in men, p<0.001.Conclusions1. In the RESCLE cohort, smoking and ILD were more frequent in males, and sicca syndrome and ANA positivity in women. 2. ILD was the most common cause of death in men and PAH in women. 3. PAH was more frequently a cause of death in women than in men. 4. Men had less survival since the onset of symptoms.ReferencesSimeόn CP et al, Br J Rheumatol 1996.Gaultier JB et al, Rev Med Interne 2008.Panopoulos ST et al, J Rheumatol 2013.Hussein H et al, J Rheumatol 2014.Elhai M et al, Ann Rheum Dis 2014.Disclosure of InterestNone declared
BackgroundSome patients with LV-GCA does not have cranial symptoms of giant cell arteritis (C-GCA) and the temporal artery biopsy (TAB) is negative for arteritis. This subset of patients usually has diagnostic delay and inappropriate treatment [1]. Furthermore, patients with biopsy-proven C-GCA and isolated ESR increase could be erroneously considered as a relapse and put on steroid treatment. In these 2 groups of patients, where clinical decisions are difficult the 18F-FDG PET/CT scan may be usefulObjectivesTo study if the realization of a PET/CT with 18F-FDG can be helpful for the diagnosis of difficult cases of LV-GCA and to evaluate relapses in patients with diagnosed C-GCA and elevated markers of inflammationMethodsSince January 2012 two groups of patients, who agree to participate, were prospectively studied at our Hospital: Group 1: Patients with clinical suspicion of C-GCA but with a negative TAB and/or patients with inflammatory general syndrome of unknown origin who did not meet criteria for C-GCA [1]. Group 2: patients with biopsy-proven C-GCA and ESR persistently elevated where relapse was considered. In the 2 groups, once the diagnostic work-up has ended, an 18F-FDG PET/CT was performedResultsA total of 22 patients were studied, 17 were women (77%) with a mean age of 72 years (range: 50-85 years). Group 1 (n=18): The main complaint was: constitutional symptoms in 13 (72%), fever of unknown origin 7 (39%), optic neuritis 1 and relapsing polymyalgia rheumatica (PMR) in another. Symptoms of upper or lower extremity claudication were present in 8 (44%) and 1 (6%) respectivelysevere, abdominal pain in 4 (22%), no patient had stroke. 4 patients (all with normal TAB) had temporal artery abnormalities. Anemia was documented in 10 patients (55%) and ESR>50 in 18 (mean 96; range: 52-140 mm/h). TAB was performed in 9 patients and was negative in all cases. PET data showed vascular uptake suggestive of LV-GCA without temporal enhancement in 16/18 (89%). No patients with a negative PET have LV-GCA: the optic neuritis was caused by B. henselae and the other improved without treatment. The patient previously diagnosed with PMR showed vascular enhancement so this information changed the treatment. In the 4 patients with abdominal pain intense uptake of the abdominal aorta was seen. Group 2 (n=4): all patients had ESR>100 mm/h. 1 patient had symptoms of PMR and the other 3 were asymptomatic. However, 2 patients were on intermittent treatment with steroids. The PET/TC was negative for arteritis in 3 patients which were followed without treatment during a mean of 16.5 months. In the other case, the PET/TC images were typical of PMR (without signs of LV-GCA) and had a good response to low doses of steroidsConclusionsThe judicious use of PET/CT was useful in the diagnosis and management of selected cases of LV-GCA and to avoid unnecessary steroid treatments in patients without vasculitis or relapseReferencesWeyand CM, Gorozny JJ. Gian-Cell Arteritis and Polymyalgia Rheumatica. N Engl J Med 2014; 371:50-7.Disclosure of Int...
BackgroundSystemic sclerosis (SSc) can virtually affect any organ system (such as lungs, kidneys, gastrointestinal tract, and heart). However, it is the pulmonary manifestations that account for the majority of deaths, especially interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH).ObjectivesOur aim was to assess the differences between severe and mild-to-moderate ILD in SSc.MethodsA descriptive study was performed, using the available data from the Spanish Scleroderma Study Group (RESCLE). ILD was deemed as serious when forced vital capacity (FVC) was <50%. Patients were classified attending the modified classification criteria proposed by LeRoy and Megdsger.ResultsFourteen referral centers for SSc participated in the registry. By April 2014, 1374 patients with SSc had been enrolled, 541 of whom (39.4%) had ILD, which was severe in 72 of them (13.2%). There were no significant differences as far as sex and age at onset is concerned. Patients with diffuse SSc presented with severe ILD more frequently than those with limited SSc (57% vs. 35%, p=0.002), as well as those who had tested positive for ATA (51% vs. 33%, p=0.005). Aditionally, prevalence of FVC<50% was higher in patients with myopathy (32% vs. 15%, p=0.002). Mean FVC was 40.2±6.4 in the severe ILD group, whilst it was 80.3±18.9 in the mild-to-moderate one (p<0.001), and mean DLco was 36.7±15.2 and 62.9±34.5, respectively (p<0.001). Likewise, DLco<70% was also more frequent among patients with severe ILD (100% vs. 69%, p<0.001), as well as mean DLco/VA (56.2±24.2 vs. 74.2±42.0, p=0.002). PAPs was equally higher when FVC<50% (42.2±18.2 vs. 35.1±13.4, p=0.034), and so was the frequency of PAPs>40mmHg (66% vs. 29%, p<0.001) and PAH by right heart catheterism (19% vs. 11%, p=0.050). Finally, by means of a multiple logistic regression, both ATA positivity [OR 0.17 (0.05–0.58), p=0.005] and low DLco [0.93 (0.91–0.95), p=0.000] were found to be related with FVC<50%ConclusionsPatients with ACA positivity and with a limited variant of SSc seem to be at lower risk of severe interstitial lung involvement. Furthermore, the presence of myopathy may contribute to explain the decrease of FVC in SSc patients.References Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 2007; 66: 940–4.LeRoy EC, Medsger TA, Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573–6. Disclosure of InterestNone declared
Background18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) is a non-invasive imaging technique commonly used in clinical oncology. 18 F-FDG accumulation is recognised as useful for diagnosing and monitoring the response to therapy in patients with some inflammatory disorders, but the role of the PET/TC in the management of these diseases is debated.ObjectivesThe aim of this study was to investigate the role of 18F-FDG PET/CT in the diagnosis of the disease and assessing disease activity in an autoimmune diseases unit, and to evaluate if the results of this image technique imply a change in clinical management.MethodsWe retrospectively reviewed all 18F-FDG PET/CT requested since August 2015 to August 2017 by our unit. Data collected were: patient demographics, reason for PET request, PET results and change in therapy.ResultsPET/CT were performed in 88 patients and were positive in 68 (77,3%) cases. Patients (49 women/39 men) had a mean age of 58,1±15,7 years (range, 27–92 years). The clinical diagnosis at the moment of ordering the PET/CT were: sarcoidosis (n=45), large-vessel vasculitis (LVV) (n=16), immunoglobulin G4-related disease (IgG4-RD) (n=9), collagen-vacular diseases (CVD) (n=7), mesenteric panniculitis (n=4), myopathy (n=4), polymyalgia rheumatica (PMR) (n=2) and ANCA-associated vasculitis (n=1). (See table 1).Abstract AB1211 – Table 1SarcoidosisLVVIgG4-RDCVDMesenteric panniculitismyopathyPMR n451697442women27(60%)13 (81,2%)1(11,1%)4(57,1%)1(25%)2(50%)1(50%)age50,9(27–8372,5 (29–92)63,7(48–8053(30–8060,566,272,5PET to the diagnosis9(20%)2 (12,5%)1(11,1%)3(42,9%)3(75%)2(50%)2(100%)PET to disease activity36(80%)14(87,5%)8(88,9%)4(57,1%)1(25%)2(50%)0Positive PET/TC36(80%)11(68,7%)6(66,7%)6(85,7%)3(75%)3(75%)2(100%)Change of therapy31(68,9%)11(68,7%)6(66,7%)7(100%)2(50%)3(75%)2(100%)PET results supported a change in therapeutic management in 71.6% of the cases. In the group of sarcoidosis there was a change in treatment in 68.9% of cases. PET/TC revealed extrapulmonary manifestations in 57,8%. All patients with extracranial manifestations of giant cell arteritis (GCA) showed uptake in PET/TC. That result supported the clinical diagnosis, although negative temporal artery biopsy. PET was useful in the diagnosis and treatment of IgG4-RD in 66,7% of cases. PET scan did not find malignancy in inflammatory myopathies nor mesenteric panniculitis.ConclusionsPET/TC is an increasingly utilised in our patients with inflammatory disorders as a support for the diagnosis and management. PET/TC detection extrapulmonary sarcoidosis may have therapeutic and prognostic clinical implications. PET may be useful in patients with GCA supicion with negative biopsy and extracranial symptoms. More studies will be necessary to establish the real role of PET/TC in autoimmune and inflammatory diseases.Disclosure of InterestNone declared
Background Progressive systemic sclerosis (PSS) is a complex multisystem connective tissue disease whith unknown aetiology, but environmental and genetic factors may play a role. Since the first association of silica exposure and PSS by Erasmus in 1957 [1], several case reports documented this co-existence [2], but with conflicting results depending on the population studied [3]. Objectives To stablish the incidence and to describe the clinical and analytical characteristics of patients with Erasmus syndrome in our health area. Methods Medical records of patients admitted to the Complejo Hospitalario Universitario of Vigo from 1994 to 2011 with the diagnosis of PSS were reviewed, selecting those with documented exposure to silica. Results During this time, the diagnosis of PSS was confirmed in 86 inpatients. 10 patients (7 of the 13 total males, 3 of the 73 total females) had also documented environmental exposure to silica dust and were selected for the study. 6 patients had worked in granite quarries, one digging tunnels and the other 3 in ceramic factories. The mean age at diagnosis of scleroderma was 51 years (range 26-76). According the classification proposed by LeRoy and Medsger [4] six were diffuse and three limited variants. Other two were diagnosed of mixed connective tissue disease. The initial symptom was Raynaud’s phenomenon (RP) in 50% and cutaneous sclerosis in 20%, having appeared a median of 1 year prior to diagnosis. Clinical manifestations at the moment of diagnosis were: dyspnoea 90%, RP 80%, esophageal dysmotility 70%, skin ulcers 40%, telangiectasia 30%, arthritis 30%, tendinopathy 20%, calcinosis and renal crisis 10%. Autoantibody positivity was observed as follows: 10 ANA (1 anticentromere pattern), 2 anti-dsDNA, 1 anti-SM, 1 anti-RNP, 6 anti-Scl70, 2 ACLA, 3 RF. In 9 patients we observed interstitial lung disease data on imaging tests. Impairment in the diffusion test was observed in 7 of the 8 patients in whom lung function studies were performed, 5 of them with also a typical restrictive ventilatory pattern and decreased forced vital capacity. Bronchoscopy and transbronchial biopsy was done in 4 patients, and fibrosis and deposition of silica was described in all samples. Transthoracic echocardiography was performed in 7 patients and estimated PASP was above 25 mmHg in 5. Right cardiac catheterization was performed only in 2 patients, with mPAP measure confirmatory of PAH. 7 patients died during follow-up, with a mean of 4.2 years from diagnosis. Cause of death was respiratory failure in 3 cases, refractory heart failure in 2, liver cirrhosis in one and unknown in another one. Conclusions Erasmus syndrome is a common condition among men with PSS who require admission in our health area, diffuse variant being predominant. Clinical course of our patients is rapidly progressive, with frequent development of cardiopulmonary mixed complications and a median survival of 4.2 years from diagnosis. References Erasmus LD. Scleroderma in goldminers of the Witwatersrand with particular referen...
BackgroundSystemic sclerosis (SSc) is a disorder with a well-known autoimmune base. There is evidence suggesting a common background with other connective tissue diseases, thus predisposing to the development of other autoimmne disorders in these patients, that is, poliautoimmunity (PAI).ObjectivesTo assess PAI in a cohort of SSc patients.MethodsA nationwide, cross-sectional study was performed including the 1928 patients enrolled in the Spanish SSc Registry (RESCLE). Ethics Committee approval was obtained by all participating centres.ResultsPrevalence of PAI was 45%, with 32% having more than one association. Most of these patients were women (93%, p<0.001), with older age at diagnosis (53,7±14,7 years, p=0.027). Regarding subtypes, PAI was singnificantly more frequent in limited cutaneous SSc (48%, p=0.004) and pre-Ssc (47%, p<0.001). Sjögren’s syndrome was by far the most common association (55%), followed by global autoimmune thyroid disorders (31%), autoimmune liver disorders (17%) and inflammatory myopathies (12%). Clinical features are shown on table 1.Abstract AB0748 – Table 1TOTALISOLATED SSCPAIp Raynaud’s Phenomenon18261005 (55%)821 (45%)1.000Digital ulcers745408 (55%)337 (45%)0.888Calcinosis322142 (44%)180 (56%)<0.001Arthritis270128 (47%)142 (53%)0.064Myositis17237 (22%)135 (78%)<0.001Gastrointestinal involvement1222632 (52%)590 (48%)<0.001ILD795399 (50,2%)396 (49.8%)<0.001PH confirmed by right heart catheterisation14866 (45%)82 (55%)0.438Heart involvement409196 (48%)213 (52%)0.001Scleroderma renal crisis4327 (63%)16 (37%)0.353We found no significant differences concerning capillaroscopy patterns, or causes of death, neither SSc-related nor non-Ssc-related.Finally, a multivariate analysis with logistic regression was performed to evaluate the risk factors for PAI, which are shown on the table 2.Abstract AB0748 – Table 2VariablesMultivariate analysisOR (95% I.C.)p value Gender2,721,87–3,98<0001Age at dianosis1,011,00–1,020012Calcinosis1,631,23–2,16<0001ILD1,371,08–1,73<0001Gastrointestinal involvement1,321,05–1,660019Centromere Ab1,411,12–1,77<0001Ro Ab1,611,18–2,18<0001ConclusionsPAI in SSc is a frequent condition that special attention in these patients. We found a rather higher prevalence compared with those published in the literature, even though the distribution of those associated disorders was similar. In our cohort, there were no remarkable differences between both groups concerning clinical manifestations (although not always statistically significant). Finally, certain circumstances should make us aware of a possible associated condition to SSc.Reference[1] Elhai M, Avouac J, Kahan A, Allanore Y. Systemic sclerosis at the crossroad of polyautoimmunity. Autoimmun Rev. 2013;12:1052–7.Disclosure of InterestNone declared
BackgroundSystemic sclerosis (SSc) is a connective tissue disease of unknown origin, with heterogeneous clinic presentation and chronical and progressive evolution. There is a subtype of SSc without cutaneous presentation designated as systemic sclerosis sine scleroderma (ssSSc) that is difficult to diagnose with a delay on it producing worse prognosis.ObjectivesThe objective of this study was analyzing demographic features, clinical presentations, the treatment and evolution of ssSSc patients from our hospital.MethodsThere were analyzed in a retrospective way the patients diagnosed of SSc in our center between 1990 and May 2015, selecting those with ssSSc.ResultsAmong the 106 patients diagnosed of SSc in this period, only 5 patients (4.7%) had ssSSc. All of them were women with an average of 51 years. 3 patients (60%) had additionally an autoimmune hypothyroidism, other a polyglandular autoimmune syndrome and the other one had no autoimmune disease. Only one patient (20%) was HTA, another was smoker and another one had dyslipidemia. None of the 5 patients had suffered exposure to toxic elements. Average time delay for diagnosis was 10 years. For 3 patients initial diagnosis was in one case primary Raynaud phenomenon, other case pulmonary arterial hypertension (PAH) essential and in another one polyglandular autoimmune syndrome. 2 of the ssSSc diagnosis were done in 2006 (coincident with the opening of our monographic office of autoimmune systemic diseases). The reason for consultation in 4 of the patients (80%) was Raynaud phenomenon (RP) that was present in all of the patients during the tracking. Only one patient (20%) had digital ulcers, 2 patients (40%) esophagitis and 1 tendinopathy. 1 patient (20%) had PAH confirmed by right coronary angiography. All patients had antinuclear antibodies (ANA) positive, 80% anticentromere. A patient presented positivity to Anti Ro and another one to anticardiolipin antibodies. Nailfold capillaroscopy was made to 4 patients (80%), being all of them pathologic (Cutolo's pattern 3 active and 1 early). Spirometry was made in 4 patients (80%) founding diffusion alteration in 3 of them. The transthoracic echocardiogram performed to all patients was pathologic in the 3 of them (60%) (1 patent ductus arteriosus, 1 PAH and 1 valvular heart disease). Regarding treatment, 3 patients (60%) were treated with calcium antagonists and 2 (40%) received bosentan, without presenting none of them any serious adverse effect. It is important to highlight that 2 patients (40%) developed limited scleroderma after 9 and 4 years of diagnosis respectively. The patient with PAH died during the tracking because of right heart failure.ConclusionsssSSc diagnosis is difficult due to the absence of the main presentation, the cutaneous one. The most frequent beginning symptom is the RP, so including this symptom in the anamnesis and stablishing screening measures in patients with RP with detection of ANAs and periungual capillaroscopy is important for an early detection to allow diagnosis improvement.Referenc...
BackgroundGiant cell arteritis (GCA) is a vasculitis affecting large vessels and it is the most frequent type in patients over 50 years old. Although glucocorticoids (GC) still remain the mainstay of treatment in all these cases there is no yet clear evidence about optimal initial dose, regimen and relapses predictors and treatment [1, 2].ObjectivesTo assess the characteristics of treatment, relapse and outcomes of a biopsy-proven GCA patients and to compare these items between groups based on initial oral prednisone dose.MethodsWe performed a retrospective review of all patients diagnosed of biopsy-proven GCA in our institution (Complejo Hospitalario Universitario de Vigo) between 1 January 2000 and 31 December 2014. Additionally, they fullfilled at least 2 of other 4 1990 ACR classification criteria. Epidemiological, clinical and laboratory data, treatment and outcome of all these patients at diagnosis and during follow-up were analysed. We also compared groups by initial oral prednisone dose (≤40mg/day vs >40mg/day) using Cox models.ResultsDuring study period 70 patients were identified and analysed. Mean age at diagnosis was 77±7 years old and fifty-one (73%) were female. Charlson index was ≤1 in 83% of cases. Most frequent presenting symptoms were headache (87%), polymyalgia rheumatica (57%) and jaw claudication (48.6%). Ischaemic manifestations at diagnosis were seen in ten patients (14.3%). Median ESR and CRP was 88±26mm/h [31–140] and 92±88mg/dL [4–326] respectively. Median delay time from first symptom until diagnosis was 2 months [0–72]. We also analysed patients divided in two groups based on initial oral predisone dose (≤40mg/day [17 patients] vs >40mg/day [53 patients]). No differences was seen in sex, age, comorbidities (including cardiovascular risk factors), antiagregants/ immunosupressive therapy use or laboratory markers. Nevertheless prednisone dose at first month (30.2mg/day vs 48.6mg/day; p=0.001), time to reach ≤5mg/day of prednisone (11.8 vs 16 months; p=0.045) and total prednisone dose (7.2 vs 11.5 grams; p=0.001) were significantly higher in >40mg/day group although we did not see more GC-related adverse effects in this group (p=0.38). During follow-up period (median 29 months [3–140]) 18 patients had at least one relapse, however we did not observe statiscal differences between both groups (18% in ≤40mg/day vs 28.8% in >40mg/day; p=0.35). Time to first relapse (12±11.3 months in ≤40 vs 16±12.9 months in >40; p=0.67) and total treatment time (28±23.5 in ≤40 vs 35±25.1 months in >40) were similar in boths groups. We could not identified any factor that was related to relapses in our multivariate analysis. Twenty-two patients died during follow-up period but none were related with GCA.ConclusionsHigh-dose prednisone was the most frequent initial treatment of GCA patients.Lower doses regimen could be as safe and effective as the high-dose regimen.Relapses were seen in ¼ of patients but we could not identified any factor associated with them.ReferencesSalvarani C, Cantini F, Hunder GG. Polymya...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.